Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 24;4(3):245-250.
doi: 10.1016/j.xfre.2023.05.005. eCollection 2023 Sep.

Macroprolactinemia: a mini-review and update on clinical practice

Katherine Koniares  1 , Claudio Benadiva  1 , Lawrence Engmann  1 , John Nulsen  1 , Daniel Grow  1
Affiliations

Macroprolactinemia: a mini-review and update on clinical practice

Katherine Koniares et al. F S Rep. .

Abstract

Hyperprolactinemia is common among infertile patients, with up to 15%-20% of women with oligomenorrhea having hyperprolactinemia. Suppression of the hypothalamic-pituitary-gonadal axis via inhibition of pulsatile gonadotropin releasing hormone because of hyperprolactinemia is a common endocrine etiology of infertility. There are 3 forms of human prolactin (PRL): monomeric PRL, dimeric PRL, and macro-PRL. Also known as big-big PRL, macro-PRL has a molecular weight >150 kDa and normally comprises 5%-10% of circulating PRL. When the predominant form of circulating PRL is macro-PRL, macroprolactinemia is diagnosed. Among patients with hyperprolactinemia, 10%-46% have macroprolactinemia. Patients with macroprolactinemia are at risk of unnecessary pituitary imaging and treatment with dopamine agonists if not correctly diagnosed. Given the high prevalence of macroprolactinemia among patients with elevated PRL levels and the different management of patients with macroprolactinemia vs true monomeric hyperprolactinemia, all patients with persistently elevated PRL levels should be screened for macro-PRL.

Keywords: Prolactin; hyperprolactinemia; macroprolactin; macroprolactinemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Macro-PRL consists of monomeric PRL complexed with IgG and nonIgG antibodies. The majority of macro-PRL (87%) consists of monomeric PRL-IgG complexes. Among the monomeric PRL-IgG complexes, 67% consist of anti-PRL autoantibodies.
Figure 2
Figure 2
All patients with hyperprolactinemia on serum testing should be assessed for macroprolactinemia. PEG = polyethylene glycol, PRL = prolactin. ∗Unless a patient has clinical presentation suggestive of simultaneous prolactinoma such as amenorrhea/oligomenorrhea and/or galactorrhea
See this image and copyright information in PMC

References

    1. Thirunavakkarasu K., Dutta P., Sridhar S., Dhaliwal L., Prashad G.R.V., Gainder S., et al. Macroprolactinemia in hyperprolactinemic infertile women. Endocrine. 2013;4:750–755. - PubMed
    1. Kasum M., Orešković S., Čehić E., Šunj M., Lila A., Ejubović E. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol. 2017;56:719–724. - PubMed
    1. Vilar L., Fleseriu M., Bronstein M.D. Challenges and pitfalls in the diagnosis of macroprolactinemia. Arq Bras Endocrinol Metabol. 2014;58:9–22. - PubMed
    1. Wallace I.R., Satti N., Courtney C.H., Leslie H., Bell P.M., Hunter S.J., et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J Clin Endocrinol Metab. 2010;95:3268–3271. - PubMed
    1. Vilar L., Vilar C.F., Lyra R., Da Conceição Freitas M. Pitfalls in the Diagnostic Evaluation of Hyperprolactinemia. Neuroendocrinology. 2019;109:7–19. - PubMed

LinkOut - more resources